Research Article
Prognostic Biomarker SLCO4A1 Is Correlated with Tumor Immune Infiltration in Colon Adenocarcinoma
Table 1
SLCO4A1 expression based on different clinical indicators.
| | Clinical indicators | Number of patients | Comparison | value |
| | Individual cancer stages | 45/110/80/39 (stage 1/stage 2/stage 3/stage 4) | Stage 1 vs. stage 2 | | | Stage 1 vs. stage 3 | | | Stage 1 vs. stage 4 | | | Stage 2 vs. stage 3 | | | Stage 2 vs. stage 4 | |
| | Patient’s race | 193/55/11 (Caucasian/African-American/Asian) | Caucasian vs. African-American | | | Caucasian vs. Asian | | | African-American vs. Asian | |
| | Patient’s gender | 156/127 (male/female) | Male vs. female | |
| | Patient’s weight | 70/74/56 (normal/extreme_weight/obese) | Normal_weight vs. extreme_weight | | | Normal_weight vs. obese | | | Extreme_weight vs. obese | |
| | Patient’s age | 12/90/149 (21-40 Yrs/41-60 Yrs/61-80 Yrs) | Age (21-40 Yrs) vs. age (41-60 Yrs) | | | Age (21-40 Yrs) vs. age (61-80 Yrs) | |
| | Histological subtype | 243/37 (adenocarcinoma/mucinous adenocarcinoma) | Adenocarcinoma vs. mucinous adenocarcinoma | |
| | Nodal metastasis status | 166/70/47 (N0/N1/N2) | N0 vs. N1 | | | N0 vs. N2 | | | N1 vs. N2 | |
| | TP53 mutation status | 160/122 (mutant/nonmutant) | Mutant vs. nonmutant | |
|
|
